Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BH3120,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hanmi Advances BH3120 Immunotherapy in Global Collaborative Cancer Trials
Details : BH3120 is designed to target PD-L1 on cancer cells and 4-1BB on immune cells. It is being evaluated in combination with pembrolizumab for the treatment of cancer.
Product Name : BH3120
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 24, 2024
Lead Product(s) : BH3120,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BH3120,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Hanmi Enters Clinical Trial Collaboration with MSD to Evaluate BH3120 and KEYTRUDA®
Details : The collaboration will support Hanmi in advancing trials for its immuno-oncology drug BH3120 combined with Keytruda in metastatic solid tumors.
Product Name : BH3120
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 23, 2024
Lead Product(s) : BH3120,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rosuvastatin Calcium,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rosuzet is a combination of rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts the precursor of cholesterol and ezetimibe, a sterol transporter, NPC1L1, which is involved in the intestinal uptake of cholesterol.
Product Name : Rosuzet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2023
Lead Product(s) : Rosuvastatin Calcium,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tuspetinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Aptose Biosciences
Deal Size : $420.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hanmi has granted Aptose exclusive worldwide rights to HM43239 for all indications. HM43239 is a well-tolerated, once-daily oral agent with validated anti-leukemic activity in a highly challenging and heterogeneous malig...
Product Name : HM43239
Product Type : Other Small Molecule
Upfront Cash : $12.5 million
September 11, 2021
Lead Product(s) : Tuspetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Aptose Biosciences
Deal Size : $420.0 million
Deal Type : Licensing Agreement
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Genexine
Deal Size : Undisclosed
Deal Type : Agreement
S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi
Details : Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of...
Product Name : GX-19N
Product Type : Vaccine
Upfront Cash : Undisclosed
May 18, 2021
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Genexine
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Eflapegrastim
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Hanmi Pharmaceutical Expects U.S. FDA Approval for 2 New Drugs
Details : Rolontis," a treatment for neutropenia and "Oraxol," as a treatment for metastatic breast cancer are under priority review by FDA. Hanmi is about to announce the results of their BLA/NDA approval respectively.
Product Name : Rolontis
Product Type : Protein
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : Eflapegrastim
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA grants fast track status to Hanmi’s investigational fatty liver med
Details : The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.
Product Name : HM15211
Product Type : Peptide
Upfront Cash : Inapplicable
July 22, 2020
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efinopegdutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : $870.0 million
Deal Type : Licensing Agreement
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide
Details : Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.
Product Name : HM12525A
Product Type : Peptide
Upfront Cash : $10.0 million
April 08, 2020
Lead Product(s) : Efinopegdutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : $870.0 million
Deal Type : Licensing Agreement
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hanmi’s anti-NASH drug candidate set to become ‘game changer’ in global pharmaceutical market
Details : Hanmi is planning to begin the global Phase 2 trials of LAPSTriple Agonist in the second quarter this year with biopsy-proven NASH patients.
Product Name : HM15211
Product Type : Peptide
Upfront Cash : Inapplicable
February 28, 2020
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hanmi Pharma to develop innovative drugs for rare diseases
Details : HM12525A is the world's first anti-obesity treatment that works as a once-weekly injection. Its efficacy was proven to be higher than existing daily-injection obesity treatment in Phase 2 trials.
Product Name : HM15211
Product Type : Peptide
Upfront Cash : Inapplicable
January 16, 2020
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable